Alireza Pishgahi on Attenuation of Memory Impairment After Ischemia
Alireza Pishgahi, President at Novagena, shared on LinkedIn:
”I am proud to announce that our valuable study on Stroke Regeneration have been published.
Looking forward to bring it from bench to bedside.”
Stroke is the second leading cause of death globally, placing a heavy burden on both public health and economies.
This study explored the impact of autologous conditioned serum (ACS) on memory and related molecular factors in a mouse model of ischemic stroke.
The findings suggest that intranasal ACS treatment after stroke improves memory, likely by elevating IGF-1 levels, reducing inflammation via IL-1β inhibition, and regulating tau protein levels.
Read the full article here.
Article: Intranasal Autologous Conditioned Serum Attenuates Memory Impairment After mPFC Ischemia in Mice
Authors: Sareh Kazmi, Neda Yazdanfar, Fatemehsadat Seyedaghamiri, Alireza Pishgahi, Mehdi Yousefi, Tahereh Ghadiri, Saeed Sadigh-Eteghad, Mehdi Farhoudi
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines